Altimmune to present at upcoming easl international liver congress™ 2025

Gaithersburg, md., may 01, 2025 (globe newswire) -- altimmune, inc. (nasdaq: alt), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (masld) utilizing the mash resolution index (mashresind; loomba 2024), a highly sensitive non-invasive measure of mash histologic response, in a poster session at the european association for the study of the liver (easl) international liver congress™ 2025 in amsterdam, the netherlands. the abstract will be featured in the conference poster session and poster tour.
ALT Ratings Summary
ALT Quant Ranking